AIM: To determine the prevalence of celiac disease in a randomly selected population sample. METHODS: A total of 2157 subjects (1036 males; 1121 females) participating in a population-based cross-sectional study underwent laboratory testing for tissue transglutaminase and antibodies to immunoglobulin A, endomysium and antigliadin. In a second step, all subjects who had been examined serologically were surveyed using a questionnaire that included questions specific to celiac disease. Subjects with positive antibody titers and those with histories positive for celiac disease then underwent biopsy. At the first follow up, antibody titers were again determined in these subjects and subjects were questioned regarding symptoms specific for celiac disease and disorders associated with celiac disease. The second follow up consisted of a telephone interview with subjects positive for celiac disease. RESULTS: Antibody tests consistent with celiac disease were reported in eight subjects, corresponding to an overall prevalence of 1:270 (8/2157). The prevalence among women was 1:224 and 1:518 in men. Classical symptoms were observed in 62.5% of subjects. Atypical celiac disease was present in 25.0%, and transient celiac disease in 12.5%. False-negative test results were returned in three subjects. This yields a sensitivity and specificity of 62.5% and 50.0%, respectively, for tissue transglutaminase immunoglobulin-A antibody; of 62.5% and 71.4% respectively, for endomysium antibody; and of 62.5% and 71.4%, respectively, for antigliadin antibody. CONCLUSION: The prevalence rate in our collective lies within the middle tertile of comparable studies in Europe. The use of a single antibody test for screening purposes must be called into question.
AIM: To determine the prevalence of celiac disease in a randomly selected population sample. METHODS: A total of 2157 subjects (1036 males; 1121 females) participating in a population-based cross-sectional study underwent laboratory testing for tissue transglutaminase and antibodies to immunoglobulin A, endomysium and antigliadin. In a second step, all subjects who had been examined serologically were surveyed using a questionnaire that included questions specific to celiac disease. Subjects with positive antibody titers and those with histories positive for celiac disease then underwent biopsy. At the first follow up, antibody titers were again determined in these subjects and subjects were questioned regarding symptoms specific for celiac disease and disorders associated with celiac disease. The second follow up consisted of a telephone interview with subjects positive for celiac disease. RESULTS: Antibody tests consistent with celiac disease were reported in eight subjects, corresponding to an overall prevalence of 1:270 (8/2157). The prevalence among women was 1:224 and 1:518 in men. Classical symptoms were observed in 62.5% of subjects. Atypical celiac disease was present in 25.0%, and transient celiac disease in 12.5%. False-negative test results were returned in three subjects. This yields a sensitivity and specificity of 62.5% and 50.0%, respectively, for tissue transglutaminase immunoglobulin-A antibody; of 62.5% and 71.4% respectively, for endomysium antibody; and of 62.5% and 71.4%, respectively, for antigliadin antibody. CONCLUSION: The prevalence rate in our collective lies within the middle tertile of comparable studies in Europe. The use of a single antibody test for screening purposes must be called into question.
Authors: A Ivarsson; L A Persson; L Nyström; H Ascher; B Cavell; L Danielsson; A Dannaeus; T Lindberg; B Lindquist; L Stenhammar; O Hernell Journal: Acta Paediatr Date: 2000-02 Impact factor: 2.299
Authors: J C Gomez; G S Selvaggio; M Viola; B Pizarro; G la Motta; S de Barrio; R Castelletto; R Echeverría; E Sugai; H Vazquez; E Mauriño; J C Bai Journal: Am J Gastroenterol Date: 2001-09 Impact factor: 10.864
Authors: Marcis Leja; Zakera Shums; Liene Nikitina-Zake; Mikus Gavars; Ilze Kikuste; Jay Milo; Ilva Daugule; Jelena Pahomova; Valdis Pirags; Vilnis Dzerve; Janis Klovins; Andrejs Erglis; Gary L Norman Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Isabel A Hujoel; Claire L Jansson-Knodell; Philippe P Hujoel; Margaux L A Hujoel; Rok Seon Choung; Joseph A Murray; Alberto Rubio-Tapia Journal: J Clin Gastroenterol Date: 2021-04-01 Impact factor: 3.174
Authors: Shadi Rashtak; Shahryar Khaleghi; Eric V Marietta; Mark R Pittelkow; Joseph J Larson; Brian D Lahr; Joseph A Murray Journal: PLoS One Date: 2015-08-19 Impact factor: 3.240